<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="59005"><DrugName>TOL-101</DrugName><DrugSynonyms><Name><Value>TOL-101</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>mAb (transplant rejection), Tolera Therapeutics</Value></Name><Name><Value>monoclonal antibody (transplant rejection), Tolera Therapeutics</Value></Name><Name><Value>anti-TCR alpha/beta antibody (transplant rejection/type 1 diabetes/multiple sclerosis), Tolera</Value></Name></DrugSynonyms><CompanyOriginator id="1015301">Tolera Therapeutics Inc</CompanyOriginator><CompaniesSecondary><Company id="1015301">Tolera Therapeutics Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="59005" type="Drug"><TargetEntity id="677978" type="siDrug">TOL-101</TargetEntity></SourceEntity><SourceEntity id="1015301" type="Company"><TargetEntity id="4298026901" type="organizationId">Tolera Therapeutics Inc</TargetEntity></SourceEntity><SourceEntity id="213" type="ciIndication"><TargetEntity id="G35" type="ICD10"></TargetEntity><TargetEntity id="10028245" type="MEDDRA"></TargetEntity><TargetEntity id="D009103" type="MeSH"></TargetEntity><TargetEntity id="-1241225595" type="omicsDisease"></TargetEntity><TargetEntity id="112" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2989" type="ciIndication"><TargetEntity id="T86.11" type="ICD10"></TargetEntity><TargetEntity id="10023439" type="MEDDRA"></TargetEntity><TargetEntity id="1136" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="515" type="ciIndication"><TargetEntity id="10044439" type="MEDDRA"></TargetEntity><TargetEntity id="D006084" type="MeSH"></TargetEntity><TargetEntity id="1133" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="836" type="ciIndication"><TargetEntity id="E10" type="ICD10"></TargetEntity><TargetEntity id="10067584" type="MEDDRA"></TargetEntity><TargetEntity id="D003922" type="MeSH"></TargetEntity><TargetEntity id="-686743471" type="omicsDisease"></TargetEntity><TargetEntity id="507" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="74844" type="Action"><TargetEntity id="4353" type="Mechanism">Anti-Invariant T cell Receptor</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsSecondary><Indication id="213">Multiple sclerosis</Indication><Indication id="2989">Kidney transplant rejection</Indication><Indication id="515">Transplant rejection</Indication><Indication id="836">Insulin dependent diabetes</Indication></IndicationsSecondary><ActionsPrimary><Action id="5741">Immunoglobulin M agonist</Action><Action id="74844">T cell receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="1596">Immunomodulator</Action></ActionsSecondary><Technologies><Technology id="167">Monoclonal antibody murine</Technology><Technology id="574">Immunoglobulin-M</Technology><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="761">Biological therapeutic</Technology></Technologies><LastModificationDate>2019-01-07T18:39:21.000Z</LastModificationDate><ChangeDateLast>2019-01-10T00:00:00.000Z</ChangeDateLast><AddedDate>2007-12-20T16:18:32.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="1015301" linkType="Company"&gt;Tolera Therapeutics&lt;/ulink&gt;, using antibody technology licensed from the &lt;ulink linkID="20600" linkType="Company"&gt;University of Kentucky&lt;/ulink&gt;, was developing TOL-101, a murine monoclonal IgM antibody against the alpha/beta T-cell receptor (alpha/beta-TCR),  for the potential treatment and prevention of transplant rejection, and is investigating it for the potential treatment of  autoimmune diseases including type 1 diabetes and multiple sclerosis (MS)    [&lt;ulink linkID="862759" linkType="Reference"&gt;862759&lt;/ulink&gt;], [&lt;ulink linkID="1109949" linkType="Reference"&gt;1109949&lt;/ulink&gt;], [&lt;ulink linkID="1217267" linkType="Reference"&gt;1217267&lt;/ulink&gt;], [&lt;ulink linkID="1217273" linkType="Reference"&gt;1217273&lt;/ulink&gt;], [&lt;ulink linkID="1217282" linkType="Reference"&gt;1217282&lt;/ulink&gt;]. In July 2010, a phase I/II trial of TOL-101 induction therapy versus Thymoglobulin began in kidney transplant patients [&lt;ulink linkID="1217289" linkType="Reference"&gt;1217289&lt;/ulink&gt;]. By October 2012, data had demonstrated the efficacy of TOL-101. At that time, the company was planning for a phase III study [&lt;ulink linkID="1332128" linkType="Reference"&gt;1332128&lt;/ulink&gt;]; in March 2013, the study was expected to begin in 2013 [&lt;ulink linkID="1392521" linkType="Reference"&gt;1392521&lt;/ulink&gt;]. In March 2013, the company was seeking to outlicense the drug [&lt;ulink linkID="1392453" linkType="Reference"&gt;1392453&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="18008" linkType="Company"&gt;MedImmune&lt;/ulink&gt; was previously developing a predecessor antibody, &lt;ulink linkID="9071" linkType="Drug"&gt;MEDI-500&lt;/ulink&gt;, under license from the &lt;ulink linkID="20600" linkType="Company"&gt;University of Kentucky&lt;/ulink&gt; [&lt;ulink linkID="1217268" linkType="Reference"&gt;1217268&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In April 2009, the FDA granted TOL-101 Orphan status for the prevention of solid organ transplant rejection [&lt;ulink linkID="999363" linkType="Reference"&gt;999363&lt;/ulink&gt;]. In June 2010, the FDA granted TOL-101 Orphan Drug status for recent-onset immune-mediated type 1 diabetes (T1DM) with preserved pancreatic beta-cell function in subjects aged 16 years and under [&lt;ulink linkID="1109949" linkType="Reference"&gt;1109949&lt;/ulink&gt;]. In January 2011, the FDA awarded the drug Orphan status for pediatricÂ MS in patients aged 16 years and under [&lt;ulink linkID="1257166" linkType="Reference"&gt;1257166&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In February 2013, the COMP adopted a positive opinion recommending the drug for the prevention of graft rejection following solid organ transplantation [&lt;ulink linkID="1383024" linkType="Reference"&gt;1383024&lt;/ulink&gt;]. By March 2013, Orphan Drug designation had been approved in Europe [&lt;ulink linkID="1392453" linkType="Reference"&gt;1392453&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In October 2012, the company was planning to submit a Special Protocol Assessment with the US FDA to initiate a phase III study of TOL-101 compared to &lt;ulink linkID="9298" linkType="Drug"&gt;Thymoglobulin&lt;/ulink&gt; [&lt;ulink linkID="1332128" linkType="Reference"&gt;1332128&lt;/ulink&gt;].  In July 2014, it was reported at the 2014 World Transplant Congress in San Francisco, CA, that the study had FDA approval and was waiting for funding to begin [&lt;ulink linkID="1579980" linkType="Reference"&gt;1579980&lt;/ulink&gt;], [&lt;ulink linkID="1581950" linkType="Reference"&gt;1581950&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2013, an end-of-phase II meeting had been completed with the FDA [&lt;ulink linkID="1392453" linkType="Reference"&gt;1392453&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In July 2010, a phase I/II trial (&lt;ulink linkID="67823" linkType="Protocol"&gt;NCT01154387&lt;/ulink&gt;; TTI-121) of TOL-101 induction therapy versus Thymoglobulin for the prophylaxis of acute organ rejection began in renal transplantation patients (estimated n = 85) in the US. The induction antibodies would be administered as part of an immunosuppressive regimen that includes steroids, &lt;ulink linkID="3669" linkType="Drug"&gt;mycophenolate mofetil&lt;/ulink&gt;, and &lt;ulink linkID="4510" linkType="Drug"&gt;tacrolimus&lt;/ulink&gt;. At that time, the trial was estimated to complete in January 2012 [&lt;ulink linkID="1217289" linkType="Reference"&gt;1217289&lt;/ulink&gt;]. By October 2012, data had demonstrated the efficacy of TOL-101 [&lt;ulink linkID="1332128" linkType="Reference"&gt;1332128&lt;/ulink&gt;]. In March 2013, clinical data were presented at IMMUNO 2013 in Barcelona, Spain. The drug was safe and well tolerated [&lt;ulink linkID="1392521" linkType="Reference"&gt;1392521&lt;/ulink&gt;]. In July 2014, data were presented at the 2014 World Transplant Congress in San Francisco, CA. Treatment with TOL-101 induced marked increases in CD3-positive cell counts and resulted in 100% patient and graft survival at 6 months. Only one serious adverse event was considered related to the study medication (a case of nosocomial pneumonia). Most adverse events were observed in patients receiving high doses of TOL-101 without escalation. The highest dose without escalation was also associated with an increased frequency of urticarial rash. All treated patients showed normal platelet and WBC counts. There was negligible release of IFN-gamma, TNF and IL-2, -6 and -10 during treatment, and a half-life of 23.8 h (at doses of 28 mg and above) [&lt;ulink linkID="1579980" linkType="Reference"&gt;1579980&lt;/ulink&gt;], [&lt;ulink linkID="1581950" linkType="Reference"&gt;1581950&lt;/ulink&gt;].  In July 2014, further data were presented at the same conference. The mean values for clearance and volume of distribution were found to be consistent across the cohorts that received 28, 32, and 42 mg. The mean t1/2 for 5 cohorts was in the range of 15 to 28.6 h, with an overall mean of 23.8 h [&lt;ulink linkID="1579948" linkType="Reference"&gt;1579948&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2009, the company filed an IND for transplantation with the FDA; at that time, further studies were expected in 2010 [&lt;ulink linkID="1054344" linkType="Reference"&gt;1054344&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;TOL-101 is of potential use for Short Course Immune Induction Therapy (SCIIT), which involves using a therapeutic agent to induce T-cell non-responsiveness, also known as operational tolerance [&lt;ulink linkID="1217282" linkType="Reference"&gt;1217282&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2008, &lt;ulink linkID="1023712" linkType="Company"&gt;Laureate Pharma&lt;/ulink&gt; signed an agreement with Tolera Therapeutics to cGMP manufacture Tolera's TOL-101 for use in clinical trials [&lt;ulink linkID="956623" linkType="Reference"&gt;956623&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1015301">Tolera Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="213">Multiple sclerosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-10-20T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1015301">Tolera Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="836">Insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-10-20T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1015301">Tolera Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2989">Kidney transplant rejection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-10-20T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1015301">Tolera Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2989">Kidney transplant rejection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-07-26T00:00:00.000Z</StatusDate><Source id="1217289" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1015301">Tolera Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="213">Multiple sclerosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-08-24T00:00:00.000Z</StatusDate><Source id="1217267" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1015301">Tolera Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="836">Insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-06-22T00:00:00.000Z</StatusDate><Source id="1109949" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1015301">Tolera Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="515">Transplant rejection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-12-20T00:00:00.000Z</StatusDate><Source id="862759" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1015301">Tolera Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="515">Transplant rejection</Indication><AwardedIndication>Prevention of graft rejection following solid organ transplantation</AwardedIndication><DesignationType id="2">Prevention</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-03-12T00:00:00.000Z</MileStoneDate><Source id="1392453" type="OTHER"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1015301">Tolera Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="515">Transplant rejection</Indication><AwardedIndication>Prevention of graft rejection following solid organ transplantation</AwardedIndication><DesignationType id="2">Prevention</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-02-06T00:00:00.000Z</MileStoneDate><Source id="1383024" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1015301">Tolera Therapeutics Inc</OwnerCompany><Country id="US">US</Country><Indication id="213">Multiple sclerosis</Indication><AwardedIndication>Treatment of pediatric multiple sclerosis in patients less than or equal to 16 years of age</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-01-12T00:00:00.000Z</MileStoneDate><Source id="1257166" type="CORPORATE"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1015301">Tolera Therapeutics Inc</OwnerCompany><Country id="US">US</Country><Indication id="836">Insulin dependent diabetes</Indication><AwardedIndication>Treatment of patients 16 years of age and younger with immune-mediated T1DM and preserved pancreatic beta cell function</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-06-07T00:00:00.000Z</MileStoneDate><Source id="1109949" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1015301">Tolera Therapeutics Inc</OwnerCompany><Country id="US">US</Country><Indication id="515">Transplant rejection</Indication><AwardedIndication>Prophylaxis of acute rejection of solid organ transplantation</AwardedIndication><DesignationType id="2">Prevention</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-04-03T00:00:00.000Z</MileStoneDate><Source id="999363" type="PR"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-01014"><Name>Immunoglobulin M</Name><SwissprotNumbers></SwissprotNumbers></Target><Target id="PTGT-12987"><Name>T cell receptor</Name><SwissprotNumbers></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1015301">Tolera Therapeutics Inc</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="1063688">Gallus BioPharmaceuticals</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20600">University of Kentucky</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="10">Technology - Other Proprietary</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="6">Drug - Manufacturing/Supply</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="117275" title="Laureate Pharma to supply Tolera Therapeutics's TOL-101 for clinical trials"></Deal><Deal id="136136" title="Tolera Therapeutics to apply University of Kentucky's antibody technology for the development of TOL-101 "></Deal></Deals><PatentFamilies><PatentFamily id="3577190" number="WO-2017049159" title="T-cell receptor (TCR) targeting therapies for immune-mediated adverse drug reactions (ADRs) and other conditions"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tolera Therapeutics Inc" id="1015301"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ledebur Consulting LLC" id="1145569"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Michigan State University" id="20624"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>